Use of a molecular syndromic panel for the etiological diagnosis of bloodstream infections in critically ill patients: impact on clinical outcomes and antimicrobial use from a multicenter, prospective study.

@article{giacobbe2026molecular,
  title = {{Use of a molecular syndromic panel for the etiological diagnosis of bloodstream infections in critically ill patients: impact on clinical outcomes and antimicrobial use from a multicenter, prospective study.}},
  author = {Daniele Roberto Giacobbe and Claudia Bartalucci and Greta Cattardico and Vincenzo Di Pilato and Marco Muccio and Maurizio Fedriga and Alessandro Limongelli and Alessio Signori and Alessandra Bandera and Bruno Cacopardo and Edoardo Campanella and Alessandro Caroli and Annamaria Cattelan and Marco Piscaglia and Andrea Cortegiani and Laura Curci and Gennaro De Pascale and Giuseppe Vittorio De Socio and Filippo Del Puente and Chiara Fanelli and Teresa Fasciana and Nicholas Geremia and Maddalena Giannella and Giacomo Grasselli and Chiara Maci and Ivana Maida and Davide Mangioni and Andrea Marino and Maria Mazzitelli and Maria Chiara Meloni and Marco Merli and Elena Momesso and Chiara Oltolini and Carlo Pallotto and Sandro Panese and Matteo Passerini and Emanuele Pontali and Daniele Riccucci and Matteo Rinaldi and Marco Ripa and Vincenzo Scaglione and Francesco Saverio Serino and Vincenzo Spagnuolo and Giulia Spurio and Stefania Tigano and Carlo Torti and Giovanna Travi and Laura Magnasco and Federica Portunato and Federica Briano and Malgorzata Mikulska and Lorenzo Ball and Chiara Robba and Nicolò Patroniti and Denise Battaglini and Mauro Giacomini and Gian Maria Rossolini and Maurizio Sanguinetti and Paola Morici and Anna Marchese},
  journal = {Annals of medicine},
  year = {2026},
  month = nov,
  doi = {10.1080/07853890.2026.2750724},
  url = {https://europepmc.org/article/MED/42968548},
  note = {CC BY},
}

TY  - JOUR
TI  - Use of a molecular syndromic panel for the etiological diagnosis of bloodstream infections in critically ill patients: impact on clinical outcomes and antimicrobial use from a multicenter, prospective study.
AU  - Daniele Roberto Giacobbe
AU  - Claudia Bartalucci
AU  - Greta Cattardico
AU  - Vincenzo Di Pilato
AU  - Marco Muccio
AU  - Maurizio Fedriga
AU  - Alessandro Limongelli
AU  - Alessio Signori
AU  - Alessandra Bandera
AU  - Bruno Cacopardo
AU  - Edoardo Campanella
AU  - Alessandro Caroli
AU  - Annamaria Cattelan
AU  - Marco Piscaglia
AU  - Andrea Cortegiani
AU  - Laura Curci
AU  - Gennaro De Pascale
AU  - Giuseppe Vittorio De Socio
AU  - Filippo Del Puente
AU  - Chiara Fanelli
AU  - Teresa Fasciana
AU  - Nicholas Geremia
AU  - Maddalena Giannella
AU  - Giacomo Grasselli
AU  - Chiara Maci
AU  - Ivana Maida
AU  - Davide Mangioni
AU  - Andrea Marino
AU  - Maria Mazzitelli
AU  - Maria Chiara Meloni
AU  - Marco Merli
AU  - Elena Momesso
AU  - Chiara Oltolini
AU  - Carlo Pallotto
AU  - Sandro Panese
AU  - Matteo Passerini
AU  - Emanuele Pontali
AU  - Daniele Riccucci
AU  - Matteo Rinaldi
AU  - Marco Ripa
AU  - Vincenzo Scaglione
AU  - Francesco Saverio Serino
AU  - Vincenzo Spagnuolo
AU  - Giulia Spurio
AU  - Stefania Tigano
AU  - Carlo Torti
AU  - Giovanna Travi
AU  - Laura Magnasco
AU  - Federica Portunato
AU  - Federica Briano
AU  - Malgorzata Mikulska
AU  - Lorenzo Ball
AU  - Chiara Robba
AU  - Nicolò Patroniti
AU  - Denise Battaglini
AU  - Mauro Giacomini
AU  - Gian Maria Rossolini
AU  - Maurizio Sanguinetti
AU  - Paola Morici
AU  - Anna Marchese
PY  - 2026
DA  - 2026/11/01
JO  - Annals of medicine
DO  - 10.1080/07853890.2026.2750724
UR  - https://europepmc.org/article/MED/42968548
AB  - Background  Bloodstream infections (BSI) frequently occur in critically ill patients and remain associated with high mortality rates.Methods  A prospective, observational, multicenter investigation was carried out through the MULTI-SITA platform to evaluate how the addition of a molecular syndromic panel, the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel (BCID2 panel), to conventional blood culture diagnostics influenced key clinical endpoints and antimicrobial use. The primary endpoint was all-cause mortality within 30 days following the onset of BSI.Results  Among the 126 included critically ill patients with BSI, multivariable analysis identified SOFA score (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.09-1.34, p < 0.001), other concomitant infections requiring antibiotic therapy (HR 2.61, 95% CI 1.18-5.79, p = 0.018), and BSI caused by Acinetobacter spp. (HR 4.35, 95% CI 1.10-17.18, p = 0.036), Staphylococcus aureus (HR 3.38, 95% CI 1.26-9.08, p = 0.016), or Stenotrophomonas maltophilia (HR 15.97, 95% CI 2.43-104.54, p = 0.004) as associated with increased mortality, while no association was observed between use of the BCID2 panel and mortality (HR 0.97, 95% CI 0.42-2.25, p = 0.941). In secondary analyses, the use of the BCID2 panel resulted in more events of either early antimicrobial de-escalation or initiation of appropriate therapy at day one from BSI onset compared with a standard blood culture workflow (55.6% vs. 31.7%, p = 0.015).Conclusion  In critically ill patients with BSI, implementation of a molecular syndromic panel influenced antimicrobial management decisions without affecting mortality. Additional investigations are warranted to clarify the long-term antimicrobial stewardship implications of treatment strategies guided by molecular syndromic panels-based diagnostic workflows.
SN  - 0785-3890
SN  - 1365-2060
ER  -